Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 12, 2011 - Issue 8
Submit an article Journal homepage
333
Views
16
CrossRef citations to date
0
Altmetric
Reviews

Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease

Jonathan R EvansUniversity of Cambridge, Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge, CB2 0SD, UK+44 7957 585975; +44 1223 331174; [email protected]
, MRCP &
Roger A BarkerUniversity of Cambridge, Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge, CB2 0SD, UK+44 7957 585975; +44 1223 331174; [email protected]
, PhD
Pages 1249-1258 | Published online: 23 Feb 2011

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Krista Farrell & Roger A Barker. (2012) Stem cells and regenerative therapies for Parkinson’s disease. Degenerative Neurological and Neuromuscular Disease 2, pages 79-92.
Read now

Articles from other publishers (15)

Thomas Morel, Sophie Cleanthous, John Andrejack, Roger A. Barker, Milton Biagioni, Geraldine Blavat, Bastiaan R. Bloem, Babak Boroojerdi, William Brooks, Paul Burns, Stefan Cano, Casey Gallagher, Lesley Gosden, Carroll Siu, Ashley F. Slagle, Natasha Ratcliffe & Karlin Schroeder. (2023) Development and early qualitative evidence of two novel patient-reported outcome instruments to assess daily functioning in people with early-stage Parkinson’s. Journal of Patient-Reported Outcomes 7:1.
Crossref
Thomas Morel, Sophie Cleanthous, John Andrejack, Roger A. Barker, Geraldine Blavat, William Brooks, Paul Burns, Stefan Cano, Casey Gallagher, Lesley Gosden, Carroll Siu, Ashley F. Slagle, Kate Trenam, Babak Boroojerdi, Natasha Ratcliffe & Karlin Schroeder. (2022) Patient Experience in Early-Stage Parkinson’s Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome Assessment. Neurology and Therapy 11:3, pages 1319-1340.
Crossref
Ioanna Markaki, Theodora Ntetsika & Per Svenningsson. (2021) Reply to: “ HbA1c and Motor Outcome in Parkinson's Disease in the Mark‐PD Study” . Movement Disorders 36:8, pages 1993-1993.
Crossref
Miguel Leal Rato, Olivier Rascol & Joaquim J. Ferreira. (2019) The “Long and Winding Road” of the Disease‐Modifying Effects of Levodopa Has Not Ended Yet. Movement Disorders 35:3, pages 397-399.
Crossref
W.G. Meissner. (2018) Stratégies thérapeutiques ciblant l’alpha-synucléine pour le traitement de la maladie de Parkinson et des autres synucléinopathies. Pratique Neurologique - FMC 9:2, pages 156-161.
Crossref
David J. M. McGhee, Craig W. Ritchie, John P. Zajicek & Carl E. Counsell. (2016) A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease. BMC Neurology 16:1.
Crossref
James M. Fisher, Nils Y. Hammerla, Thomas Ploetz, Peter Andras, Lynn Rochester & Richard W. Walker. (2016) Unsupervised home monitoring of Parkinson's disease motor symptoms using body-worn accelerometers. Parkinsonism & Related Disorders 33, pages 44-50.
Crossref
James M. FisherNils Y. HammerlaLynn RochesterPeter AndrasRichard W. Walker. (2016) Body-Worn Sensors in Parkinson's Disease: Evaluating Their Acceptability to Patients. Telemedicine and e-Health 22:1, pages 63-69.
Crossref
Linda A. Winters-Miner, Pat S. Bolding, Joseph M. Hilbe, Mitchell Goldstein, Thomas Hill, Robert Nisbet, Nephi Walton & Gary D. Miner. 2015. Practical Predictive Analytics and Decisioning Systems for Medicine. Practical Predictive Analytics and Decisioning Systems for Medicine 116 132 .
Pierre-Olivier Fernagut, Benjamin Dehay, Aline Maillard, Erwan Bezard, Paul Perez, Anne Pavy-Le Traon, Olivier Rascol, Alexandra Foubert-Samier, François Tison & Wassilios G. Meissner. (2014) Multiple system atrophy: A prototypical synucleinopathy for disease-modifying therapeutic strategies. Neurobiology of Disease 67, pages 133-139.
Crossref
Zinovia Kefalopoulou & Tom Foltynie. (2013) How can we judge the ‘long term’ outcomes of novel interventions in Parkinson’s disease?. NeuroReport 24:18, pages 1005-1009.
Crossref
Roger A Barker, Jessica Barrett, Sarah L Mason & Anders Björklund. (2013) Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. The Lancet Neurology 12:1, pages 84-91.
Crossref
Connie Marras. (2012) How will epidemiology shape our knowledge of the patterns of disease progression in Parkinson’s disease?. Basal Ganglia 2:4, pages 171-174.
Crossref
C. Warren Olanow & Ole Isacson. (2012) Stem cells for Parkinson's disease: Advancing science but protecting patients. Movement Disorders 27:12, pages 1475-1477.
Crossref
Jonathan R. Evans, Sarah L. Mason & Roger A. Barker. 2012. Functional Neural Transplantation III - Primary and Stem Cell Therapies for Brain Repair, Part I. Functional Neural Transplantation III - Primary and Stem Cell Therapies for Brain Repair, Part I 169 198 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.